As of 2025-09-17, the EV/EBITDA ratio of Cardiff Oncology Inc (CRDF) is -2.27. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Cardiff's latest enterprise value is 122.28 mil USD. Cardiff's TTM EBITDA according to its financial statements is -53.94 mil USD. Dividing these 2 quantities gives us the above Cardiff EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.4x - 14.3x | 13.4x |
| Forward P/E multiples | 16.3x - 33.6x | 19.1x |
| Fair Price | (13.05) - (11.42) | (13.01) |
| Upside | -752.7% - -670.8% | -750.6% |
| Date | EV/EBITDA |
| 2025-09-16 | -2.27 |
| 2025-09-15 | -2.32 |
| 2025-09-12 | -2.33 |
| 2025-09-11 | -2.37 |
| 2025-09-10 | -2.32 |
| 2025-09-09 | -2.43 |
| 2025-09-08 | -2.55 |
| 2025-09-05 | -2.48 |
| 2025-09-04 | -2.43 |
| 2025-09-03 | -2.22 |
| 2025-09-02 | -2.21 |
| 2025-08-29 | -2.39 |
| 2025-08-28 | -2.37 |
| 2025-08-27 | -2.48 |
| 2025-08-26 | -2.53 |
| 2025-08-25 | -2.53 |
| 2025-08-22 | -2.66 |
| 2025-08-21 | -2.59 |
| 2025-08-20 | -2.61 |
| 2025-08-19 | -2.64 |
| 2025-08-18 | -2.80 |
| 2025-08-15 | -2.81 |
| 2025-08-14 | -2.81 |
| 2025-08-13 | -2.82 |
| 2025-08-12 | -2.80 |
| 2025-08-11 | -2.67 |
| 2025-08-08 | -2.75 |
| 2025-08-07 | -2.77 |
| 2025-08-06 | -2.81 |
| 2025-08-05 | -2.97 |
| 2025-08-04 | -2.90 |
| 2025-08-01 | -3.06 |
| 2025-07-31 | -2.72 |
| 2025-07-30 | -2.87 |
| 2025-07-29 | -3.88 |
| 2025-07-28 | -4.40 |
| 2025-07-25 | -4.70 |
| 2025-07-24 | -4.91 |
| 2025-07-23 | -5.09 |
| 2025-07-22 | -4.46 |
| 2025-07-21 | -4.62 |
| 2025-07-18 | -5.08 |
| 2025-07-17 | -5.29 |
| 2025-07-16 | -5.25 |
| 2025-07-15 | -4.88 |
| 2025-07-14 | -4.89 |
| 2025-07-11 | -4.82 |
| 2025-07-10 | -4.93 |
| 2025-07-09 | -4.83 |
| 2025-07-08 | -4.66 |